Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enabling Personalized Dose Formulation by Evaporative Crystallization Process.

Pharmaceutical research·2026
Same author

Evaporative coupled with antisolvent crystallization for additive manufacturing of personalized solid dosage forms.

International journal of pharmaceutics·2026
Same author

Leveraging Machine Learning to Predict Warfarin Sensitivity in the Puerto Rican Population: A Pharmacogenomic Approach.

International journal of environmental research and public health·2026
Same author

M6 metabolite contributes to the efficacy of the Rac/Cdc42 inhibitor MBQ-167 in metastatic breast cancer.

Molecular cancer therapeutics·2026
Same author

Addressing genetic diversity and health inequities: RELIVAF's proposal for Latin American pharmacogenomic guidelines.

Frontiers in pharmacology·2026
Same author

Forecasting the Biological Effect of PEGylated-rHuEPO Candidates in Chronic Kidney Disease Patients using a Middle-out Translation Approach.

Pharmaceutical research·2026

Related Experiment Video

Updated: Jun 13, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Implementing genotype-guided antithrombotic therapy.

Richard L Seip1, Jorge Duconge, Gualberto Ruaño

  • 1Genomas, Inc., 67 Jefferson Street, Hartford, CT 06106, USA.

Future Cardiology
|May 14, 2010
PubMed
Summary

Genetic testing can personalize antithrombotic drug dosing for improved safety and efficacy. Understanding genetic variations in VKORC1 and CYP enzymes helps optimize warfarin and clopidogrel therapy, reducing adverse events.

Related Experiment Videos

Last Updated: Jun 13, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Area of Science:

  • Pharmacogenomics
  • Clinical Pharmacology
  • Drug Metabolism

Background:

  • Antithrombotic drugs like warfarin and clopidogrel exhibit significant inter-individual variability in efficacy and safety.
  • Genetic factors, particularly variations in VKORC1 and cytochrome P450 enzymes, are known to influence drug response.

Purpose of the Study:

  • To highlight the potential of genetic testing (genotyping) in optimizing the dosing and improving the safety and efficacy of major antithrombotic medications.
  • To discuss the impact of specific genetic alleles on warfarin and clopidogrel response.

Main Methods:

  • Review of genetic variations (VKORC1 -1639G>A, CYP2C9*2, *3, CYP2C19*2, *3) and their association with drug metabolism and response.
  • Mention of ongoing clinical trials (COAG, EU-PACT) investigating pharmacogenetic dosing strategies.

Main Results:

  • Specific VKORC1 and CYP2C9 alleles explain a substantial portion of warfarin dose variability across different populations.
  • CYP2C19 loss-of-function alleles reduce clopidogrel activation, leading to diminished platelet inhibition and increased cardiovascular event risk.

Conclusions:

  • Genotyping for VKORC1 and CYP enzymes is crucial for personalized warfarin and clopidogrel therapy.
  • Pharmacogenetic dosing strategies hold promise for enhancing antithrombotic treatment outcomes.
  • Regulatory bodies like the US FDA acknowledge the importance of genetic information in drug labeling for these agents.